Phase 2
N=51
The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly
Treatment · Placebo
Bottom Line
View on ClinicalTrials.gov: NCT01361633 ↗Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcome: Primary: California Verbal Learning Test-II (CLVT-II) — 55.84; 55.39 age adjusted t-scores
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- d-cycloserine (Drug); Sugar Pill (Drug)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- Hartford Hospital
- Primary completion
- Feb 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY California Verbal Learning Test-II (CLVT-II) |
55.84; 55.39 | — |
| SECONDARY Continuous Performance Test |
479.50; 507.80 | — |
| SECONDARY Controlled Oral Word Association Test |
49.58; 46.91 | — |
| SECONDARY Wisconsin Card Sort Test |
53.50; 53.70 | — |
| SECONDARY Trails B |
52.16; 48.83 | — |
| SECONDARY Stroop |
44.68; 43.30 | — |
| SECONDARY Implicit Memory Task |
3.16; 2.00 | — |
Summary
The goal of this study is to determine whether a study medication (d-cycloserine) improves the ability of older adults to perform on tests of neuropsychological functioning. Tests of neuropsychological functioning assess attention, memory, and executive functioning skills (for example, problem-solving, planning and organizing skills). It was hypothesized that participants who received study medication would perform better on neuropsychological tests than would participants who received the sugar pill.
Eligibility Criteria
Inclusion Criteria
- age 60 or older
- native English speaker
Exclusion Criteria
- diagnosis of current psychiatric disorder
- substance abuse past 3 months
- cognitive impairment
- neurological disorder
- poor health or unstable medical condition
- positive toxicology screen
- current use of isoniazid
- current use of trecator
- severe renal insufficiency
Data sourced from ClinicalTrials.gov (NCT01361633). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.